Resverlogix Corp. (RVX.TO)
-Toronto 3.65 
0.15(3.95%) May 21
| Prev Close: | 3.80 |
|---|
| Open: | 3.70 |
|---|
| Bid: | 3.65 |
|---|
| Ask: | 3.68 |
|---|
| 1y Target Est: | 6.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.60 - 3.83 |
|---|
| 52wk Range: | 1.29 - 3.83 |
|---|
| Volume: | 340,592 |
|---|
| Avg Vol (3m): | 120,394 |
|---|
| Market Cap: | 270.92M |
|---|
| P/E (ttm): | 60.83 |
|---|
| EPS (ttm): | 0.06 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Resverlogix's Board Approves Arrangement to Spin-Out RVX Therapeutics Inc. and Confirms Special Meeting of ShareholdersCNW Group(Wed, May 1)
- Resverlogix's Board Approves Arrangement to Spin-Out RVX Therapeutics Inc. and Confirms Special Meeting of ShareholdersPR Newswire(Wed, May 1)
- Canada Stocks to Watch: Rogers, SNC-Lavalin, Ivanplatsat The Wall Street Journal(Thu, Apr 18)
- Resverlogix Completes Dosing In ASSURE Clinical TrialCNW Group(Thu, Apr 18)
- Resverlogix Completes Dosing In ASSURE Clinical TrialPR Newswire(Thu, Apr 18)
- Pharma company Resverlogix to spin off unitat Reuters(Mon, Apr 8)
- Resverlogix to Spin-out RVX Therapeutics Inc. to ShareholdersCNW Group(Mon, Apr 8)
- Resverlogix to Spin-out RVX Therapeutics Inc. to ShareholdersPR Newswire(Mon, Apr 8)
- Resverlogix Secures Increase to Citibank Loan to $38.8 millionCNW Group(Mon, Mar 11)
- Resverlogix Secures Increase to Citibank Loan to $38.8 millionPR Newswire(Mon, Mar 11)
- Resverlogix comments on steady climb of share priceCNW Group(Thu, Jan 31)
- Four Biotech Ideas With Legs to Runat Motley Fool(Mon, Sep 24)
- Resverlogix Rises on Heart Drug Study Results: Calgary Moverat Bloomberg(Tue, Aug 28)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Apr-12)
: | N/A |
|---|
| Quarterly EPS Est
(Jan-12)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Resverlogix Corp., a biotechnology company, engages in the development of novel therapies for cardiovascular disease (CVD), cancer, and fibrotic diseases.
View More